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Abstract
The Congress covered the broad field of rheumatology, with participants from China, the Asia
Pacific League of Associations for Rheumatology (APLAR) region and the rest of the world.
The programme consisted of a mix of plenary lectures, concurrent symposia, workshops, free
paper sessions and poster presentations. Basic sciences were well represented, with the
general theme of inflammatory cytokines being of particular interest. One plenary lecture and a
number of other presentations addressed the problem of atherosclerosis and rheumatic
diseases. Diseases prominent in the region, such as Behcet’s disease and Takayasu’s
disease, were represented with large series. Other areas of interest were musculoskeletal
infections in HIV-positive patients and the management of spondyloarthritis. Although the use
of the most recently developed drugs is restricted in the APLAR region because of cost
factors, there were symposia on the latest pharmacological advances such as COX-2
technology, leflunomide and anti-tumour necrosis factor (TNF) therapy.
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APLAR = Asia Pacific League of Associations for Rheumatology; AS = ankylosing spondylitis; CRP = C-reactive protein ESR = erythrocyte sedimenta-
tion rate; IL-1Ra = interleukin 1 receptor antagonist; IVDU = intravenous drug user; NOD = non-obese diabetic; NSAID = nonsteroidal anti-inflammatory
drug; OA = osteoarthritis; ODF = osteoclast differntiation factor; PBMC = peripheral blood mononuclear cells; PCP = pulse cyclophosphamide; RA =
rheumatoid arthritis; SSc = systemic sclerosis; sTNF-RI = pegylated soluble tumour necorsis factor receptor I; TNF = tumour necrosis factor.
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Introduction
The Ninth Asia Pacific League of Associations for Rheuma-
tology (APLAR) Congress was held in conjunction with the
Chinese Rheumatology Association Congress of Rheumatol-
ogy in Beijing, China, from May 21–26, 2000. The meeting
was jointly organised by the Chinese Rheumatology Associ-
ation and the Chinese Medical Association. There were
approximately 2000 registrants, with 400 from China and
others from the APLAR region and other Leagues.
The meeting consisted of 20 plenary lectures, 39 concur-
rent symposia, 17 workshops, six free paper sessions and
four poster sessions. Altogether there were 263 oral and
468 poster presentations. The broad area of rheumatology
was covered during the meeting; this report will concen-
trate on some highlights of the Congress.
Review
Inflammatory cytokines
M Bendele et al (University of Colorado and Amgen Inc.,
USA) described the effects of interleukin 1 receptor
antagonist (IL-1Ra, in a hyaluronic acid slow-release
vehicle), pegylated soluble TNF receptor I (sTNF-RI) and
both used simultaneously in several animal models of
arthritis. IL-1Ra and pegylated sTNF-RI are the recombi-
nant human forms of naturally occurring inhibitors of theseArthritis Research    Vol 2 No 5 Barraclough
cytokines. There was increased benefit from the combina-
tion, providing a preclinical rationale for investigating the
potential for combination therapy with these cytokine
inhibitors in early phase clinical trials.
Li Yigong (Fuzhou General Hospital, China) and Shi
Guiying (PLA General Hospital, Beijing, China) investi-
gated Th1 and Th2 subsets at the sites of rheumatoid
inflammation, and also the expression of IL-18 in rheuma-
toid arthritis (RA) joints at both mRNA and protein levels,
in an attempt to understand the relationships between the
expression of IL-18 and the ratio of Th1 to Th2 cells, and
between IL-18 levels and disease activity. They found that
levels of IL-18, IL-4 and IFN-g mRNA were higher in
peripheral blood mononuclear cells (PBMCs) and syn-
ovial tissue in RA patients than in osteoarthritis (OA)
patients and controls. Positive immunohistochemical
staining for IL-18 antibody was found in all RA synovial
tissues, but infrequently in OA synovium, and was absent
in controls. In situ hybridisation with an IL-18 probe
showed similar results. A positive correlation was seen
between IL-18 mRNA levels and IFN-g mRNA from syn-
ovial and PBMC samples in RA, and also between IL-18
mRNA levels and disease activity (as assessed by ery-
throcyte sedimentation rate [ESR] and C-reactive protein
[CRP] levels). They concluded that IL-18 may be involved
in stimulating the IFNg-dominated Th1 responses in
inflammatory sites in rheumatoid arthritis and may be
related to disease activity.
William Arend et al (University of Colorado, USA) exam-
ined the roles of the secreted isoform of IL-1Ra (sIL-1Ra)
and of the intracellular isoform (icIL-1Ra) in human and
murine cultured cells and in murine collagen-induced
arthritis. They concluded that IL-1Ra exerts anti-inflamma-
tory effects outside cells by blocking IL-1R binding and
inside cells by inhibiting phosphorylation of key signal
transduction pathways.
The results of a study on the effect of treatment with pegy-
lated recombinant human soluble tumor necrosis factor-
type 1 receptor (PEG sTNF-R1) on the progression of dia-
betes and sialadenitis in the non-obese diabetic (NOD)
mouse model (with mice aged 8-25 weeks) were pre-
sented by R Fox et al (Scripps Medical and Research
Foundation, USA). Treatment blocked the development of
autoimmunity (both diabetes and sialadenitis) in contrast
to findings in previous reports showing increased cases of
diabetes when adult NOD mice were treated with anti-
TNF antibodies. TNF may play a role in Sjögren’s syn-
drome and type 1 diabetes.
Mononuclear cells and formation of osteoclasts
The role of TNF-a and IL-1a on synovial macrophage–
osteoclast differentiation was reported by Y Fujikawa et al
(Oita Medical University, Japan). Their studies showed
that TNF induces RA synovial macrophage–osteoclast
differentiation and that IL-1a activates osteoclasts to
resorb bone. Osteoclast formation and activation was inde-
pendent of the osteoclast differentiation factor (ODF) sig-
nalling system. Bone resorption in response to IL-1a/TNF
may have an important role in RA joint destruction.
I Itonaga et al (Oita Medical University, Japan) had previ-
ously shown that osteoclastic bone-resorbing cells were
derived in vitro from macrophages isolated from arthro-
plasty specimens. Their current study investigates whether
macrophages that have phagocytosed particles are
capable of differentiating into osteoclastic bone-resorbing
cells. Particle-phagocytic macrophages in the pseudo-
membrane surrounding the implant (latex particles) not
only produced cytokines, but also differentiated into
osteoclasts. This may influence bone resorption and lead
to loosening of a prosthesis.
Atherosclerosis and rheumatic diseases 
Yehuda Schoenfeld (Tel Aviv University, Israel) discussed
the role of autoimmunity in atherosclerosis in a plenary
lecture. His group has previously shown that immunisation
of low-density lipoprotein (LDL)-receptor-deficient mice
with b2 glycoprotein-1 (b2GP1), a principal target of
‘auto-immune’ antiphospholipid antibodies, enhances early
atherosclerosis. He reported studies showing direct evi-
dence for a role of antigen (b2GP1)-reactive T cells in pro-
moting atherosclerotic lesions in these mice.
JK Alkaabi et al (Ninewells Hospital and Medical School,
Dundee, Scotland) presented data on the prevalence of
macrovascular disease in RA. RA patients had an
increased prevalence of lower limb arterial disease. The
prevalence of smoking, diastolic blood pressure levels and
glucose levels were similar in the RA and control groups.
The intima-media thickness, as assessed by carotid duplex
scans, suggested this was atherosclerotic in nature. Sys-
tolic blood pressure was significantly higher in the RA
patients (138 versus 125 mmHg) and 60% of the RA
patients had been on steroids for more than 3 months,
possibly contributing to the higher rate of ischaemic heart
disease in this group of patients. 
YB Park et al (Yonsei University College, Korea) studied
the effect of anti-inflammatory treatment on lipid profiles
before and after treatment in 42 RA patients not previ-
ously treated with steroids or disease-modifying
antirheumatic drugs. They showed that HDL-cholesterol
and apolipoprotein A1 (apoA1) levels were significantly
higher and the ratio of apoB/apoA1 significantly lower
after treatment. Patients with active, uncontrolled RA had
altered lipid profiles which might expose them to a higher
risk of atherosclerosis. The suppression of inflammation in
RA not only helped control the arthritis, but also lowered
the risk of cardiovascular disease.http://arthritis-research.com/content/2/5/395
Meilien Ho et al (Ninewells Hospital and Medical School,
Dundee, Scotland) have previously reported an increased
prevalence of macrovascular disease in systemic sclerosis
(SSc). Basic atherosclerotic risk factor profiling had not
shown a cause for this. In this study, they investigated
whether elevated homocysteine and oxidised LDL
(OxLDL) levels might be involved. SSc patients had a
trend to higher homocysteine levels, possibly caused by
malabsorption of folate. OxLDL levels were higher in
diffuse SSc, reflecting increased oxidative stress. These
findings may contribute to the increased severity of vascu-
lar disease in SSc patients.
Spondyloarthritis
Muhammad Khan (Metro-Health Medical Centre, Cleve-
land, USA) discussed the treatment of ankylosing
spondylitis (AS). Patient education enhances compliance
with drug therapy and a regular lifelong exercise pro-
gramme. Nonsteroidal anti-inflammatory drugs (NSAIDs)
should be used at their full anti-inflammatory doses.
Studies of COX-2-specific NSAIDs are under way. Con-
current use of more than one NSAID provides little extra
benefit but increased toxicity. Sulphasalazine may be
helpful for peripheral arthritis, but has little effect on axial
arthritis or enthesitis. Oral steroids are of no value in the
long-term management of musculoskeletal aspects of AS
but local steroids for recalcitrant peripheral joint synovitis,
enthesitis or sacroiliitis can provide short-term relief.
Peripheral synovitis may respond to methotrexate. Studies
of other agents, such as thalidomide and pamidronate, are
under way. Preliminary studies suggest that anti-TNF
therapy may hold great promise in severe AS unrespon-
sive to conventional therapy, with a rapid clinical improve-
ment and a dramatic fall in acute phase reactants
occurring in an open study.
F Huang and J Gu (PLA General Hospital, Beijing, China)
reported an open study of five patients with refractory AS
treated with thalidomide. Four responded, with only minor
adverse effects. Z Ye et al (Shenzhen People’s Hospital,
China) reported a study in AS comparing thalidomide
(n = 29) with sulphasalazine (n = 37) and with NSAIDs
alone (n = 32). Thalidomide and sulphasalazine were more
effective than the NSAID group, with no major differences
between these two agents. Adverse effects were more
common with thalidomide, but they were not serious.
GC Liang and WG Barr (Northwest Medical School,
Chicago, USA) presented an open study of leflunomide
in 12 patients with recalcitrant psoriatic arthritis. Eight
had moderate to marked improvement in both psoriasis
and arthritis. 
Musculoskeletal infections in patients with HIV infection 
W Louthrenoo (Chang Mai University, Thailand) reviewed
musculoskeletal infections in patients with HIV infection.
These are not uncommon in northern Thailand, where HIV
infection is endemic. Staphylococcus aureus is the most
common organism in bone and joint infection in HIV-posi-
tive intravenous drug users (IVDUs). Non-IVDUs usually
had non-typhoidal salmonella, streptococci or other Gram-
negative bacteria. Although acute monoarthritis and
oligoarthritis are common presentations, polyarthritis is
also seen. The arthritis usually involves large joints. Fungal
bone and joint infections are not uncommon, usually due
to Penicillium marneffei, a dimorphic fungus endemic in
north Thailand and southern China. 
Behcet’s Disease
F Davatchi (Tehran University, Iran) presented a compara-
tive study of eight treatment methods for ocular manifesta-
tions in 1056 patients with Behcet’s disease. The
treatments used in this open, nonrandomised study were
pulse cyclophosphamide (PCP), low dose PCP, oral
cyclophosphamide, weekly methotrexate, chlorambucil,
cyclosporine A, azathioprine, and combined low-dose
PCP and methotrexate. Patients had active posterior
uveitis and/or retinal vasculitis. The majority of patients in
each group improved, with no significant differences
between groups.
F Khosravi and S Samangooei (Nemazi Hospital, Shiraz,
Iran) reported findings in 15 Behcet’s patients from south-
west Iran who had central nervous system involvement (out
of a total cohort of 500 Behcet’s patients). Nine presented
with a thrombotic cerebrovascular accident, one with a
cerebral artery aneurysm, three with raised intracranial
pressure, one with facial and neck swelling, one with
tonic/clonic convulsion and one with aseptic meningitis.
Central venous sinus thrombosis was subsequently
detected in four patients. Thirteen were male and two
female. The mean age was 27.4 years (11–45). The mean
interval between onset of disease and CNS involvement
was 9 years; the mean follow up was 4.5 years (8 months
to 12 years). Five patients had CNS involvement as the first
disease manifestation. At final follow up, twelve patients
were fully functional, two had degrees of gait abnormalities
and one remained bedridden. This is interesting because of
the regional bias and the large series studied.
Takayasu’s arteritis
S Jain et al (Postgraduate Institute of Medical Education
and Research, Chandigarh, India) presented the clinical
profile of 124 patients with Takayasu’s arteritis seen from
1979–1999 at a tertiary care hospital. The diagnosis was
established on aortography or autopsy. There were 77
females and 47 males. The mean age was 27.8 ± 9.1
years. Hypertension was the most common mode of pre-
sentation (76%), with Takayasu’s arteritis being the com-
monest cause of secondary hypertension in India. This is
interesting because of the regional bias and the large
series studied.Conclusion
The Congress consisted of a well balanced mix of review
sessions and presentations of basic and clinical research.
There was strong regional representation as well as
involvement from participants and speakers from other
areas worldwide.
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